ArticleJournal of gastrointestinal oncology2026

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.

Yuting Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.